A novel inhibitory nucleo-cortical circuit controls cerebellar Golgi cell activity

  1. Lea Ankri
  2. Zoé Husson
  3. Katarzyna Pietrajtis
  4. Rémi Proville
  5. Clément Léna
  6. Yosef Yarom
  7. Stéphane Dieudonné  Is a corresponding author
  8. Marylka Yoe Uusisaari
  1. Hebrew University of Jerusalem, Israel
  2. Ecole Normale Supérieure, France

Abstract

The cerebellum, a crucial center for motor coordination, is composed of a cortex and several nuclei. The main mode of interaction between these two parts is considered to be formed by the inhibitory control of the nuclei by cortical Purkinje neurons. We now amend this view by showing that inhibitory GABA-glycinergic neurons of the cerebellar nuclei project profusely into the cerebellar cortex, where they make synaptic contacts on a GABAergic subpopulation of cerebellar Golgi cells. These spontaneously firing Golgi cells are inhibited by optogenetic activation of the inhibitory nucleo-cortical fibers both in vitro and in vivo. Our data suggest that the cerebellar nuclei may contribute to the functional recruitment of the cerebellar cortex by decreasing Golgi cell inhibition onto granule cells.

Article and author information

Author details

  1. Lea Ankri

    Department of Neurobiology, Edmond and Lily Safra Center for Brain Sciences, Hebrew University of Jerusalem, Jerusalem, Israel
    Competing interests
    The authors declare that no competing interests exist.
  2. Zoé Husson

    Inhibitory Transmission Team, Institut de Biologie de l'École Normale Supérieure, Ecole Normale Supérieure, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  3. Katarzyna Pietrajtis

    Inhibitory Transmission Team, Institut de Biologie de l'École Normale Supérieure, Ecole Normale Supérieure, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  4. Rémi Proville

    Centre national de la recherche scientifique, Institut de Biologie de l'École Normale Supérieure, Ecole Normale Supérieure, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  5. Clément Léna

    Centre national de la recherche scientifique, Institut de Biologie de l'École Normale Supérieure, Ecole Normale Supérieure, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  6. Yosef Yarom

    Department of Neurobiology, Edmond and Lily Safra Center for Brain Sciences, Hebrew University of Jerusalem, Jerusalem, Israel
    Competing interests
    The authors declare that no competing interests exist.
  7. Stéphane Dieudonné

    Inhibitory Transmission Team, Institut de Biologie de l'École Normale Supérieure, Ecole Normale Supérieure, Paris, France
    For correspondence
    dieudon@biologie.ens.fr
    Competing interests
    The authors declare that no competing interests exist.
  8. Marylka Yoe Uusisaari

    Department of Neurobiology, Edmond and Lily Safra Center for Brain Sciences, Hebrew University of Jerusalem, Jerusalem, Israel
    Competing interests
    The authors declare that no competing interests exist.

Reviewing Editor

  1. Michael Häusser, University College London, United Kingdom

Ethics

Animal experimentation: All animal manipulations were made in strict accordance with guidelines of the Centre National de la Recherche Scientifique and the Hebrew University's Animal Care and Use Committee (Ethic permission # NS-12-12505-4).

Version history

  1. Received: December 27, 2014
  2. Accepted: May 11, 2015
  3. Accepted Manuscript published: May 12, 2015 (version 1)
  4. Version of Record published: June 10, 2015 (version 2)

Copyright

© 2015, Ankri et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,867
    Page views
  • 774
    Downloads
  • 70
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, Scopus, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Lea Ankri
  2. Zoé Husson
  3. Katarzyna Pietrajtis
  4. Rémi Proville
  5. Clément Léna
  6. Yosef Yarom
  7. Stéphane Dieudonné
  8. Marylka Yoe Uusisaari
(2015)
A novel inhibitory nucleo-cortical circuit controls cerebellar Golgi cell activity
eLife 4:e06262.
https://doi.org/10.7554/eLife.06262

Share this article

https://doi.org/10.7554/eLife.06262

Further reading

    1. Neuroscience
    Kiwamu Kudo, Kamalini G Ranasinghe ... Srikantan S Nagarajan
    Research Article

    Alzheimer’s disease (AD) is characterized by the accumulation of amyloid-β and misfolded tau proteins causing synaptic dysfunction, and progressive neurodegeneration and cognitive decline. Altered neural oscillations have been consistently demonstrated in AD. However, the trajectories of abnormal neural oscillations in AD progression and their relationship to neurodegeneration and cognitive decline are unknown. Here, we deployed robust event-based sequencing models (EBMs) to investigate the trajectories of long-range and local neural synchrony across AD stages, estimated from resting-state magnetoencephalography. The increases in neural synchrony in the delta-theta band and the decreases in the alpha and beta bands showed progressive changes throughout the stages of the EBM. Decreases in alpha and beta band synchrony preceded both neurodegeneration and cognitive decline, indicating that frequency-specific neuronal synchrony abnormalities are early manifestations of AD pathophysiology. The long-range synchrony effects were greater than the local synchrony, indicating a greater sensitivity of connectivity metrics involving multiple regions of the brain. These results demonstrate the evolution of functional neuronal deficits along the sequence of AD progression.

    1. Medicine
    2. Neuroscience
    Luisa Fassi, Shachar Hochman ... Roi Cohen Kadosh
    Research Article

    In recent years, there has been debate about the effectiveness of treatments from different fields, such as neurostimulation, neurofeedback, brain training, and pharmacotherapy. This debate has been fuelled by contradictory and nuanced experimental findings. Notably, the effectiveness of a given treatment is commonly evaluated by comparing the effect of the active treatment versus the placebo on human health and/or behaviour. However, this approach neglects the individual’s subjective experience of the type of treatment she or he received in establishing treatment efficacy. Here, we show that individual differences in subjective treatment - the thought of receiving the active or placebo condition during an experiment - can explain variability in outcomes better than the actual treatment. We analysed four independent datasets (N = 387 participants), including clinical patients and healthy adults from different age groups who were exposed to different neurostimulation treatments (transcranial magnetic stimulation: Studies 1 and 2; transcranial direct current stimulation: Studies 3 and 4). Our findings show that the inclusion of subjective treatment can provide a better model fit either alone or in interaction with objective treatment (defined as the condition to which participants are assigned in the experiment). These results demonstrate the significant contribution of subjective experience in explaining the variability of clinical, cognitive, and behavioural outcomes. We advocate for existing and future studies in clinical and non-clinical research to start accounting for participants’ subjective beliefs and their interplay with objective treatment when assessing the efficacy of treatments. This approach will be crucial in providing a more accurate estimation of the treatment effect and its source, allowing the development of effective and reproducible interventions.